Flow cytometry can find a cell population in seconds, but naming it consistently across labs is a problem still unsolved. If you’ve ever tried to compare cytometry data across studies, CROs, or even two scientists in the same lab, you know the frustration: everyone gates their own way,…

ADCs are one of the fastest-growing therapeutic classes in drug development, with 80+ candidates now in the clinical pipeline. But every ADC creates multiple bioanalytical questions: free payload, conjugated payload, total antibody, and beyond. Each requires its own sample prep strategy, extraction decisions, and sensitivity considerations. In this…

This talk explores the expanding role of flow cytometry in CAR-T and cellular therapy bioanalysis—from its origins supporting the earliest autologous CAR-T clinical trials to its expanding role in next-generation in vivo CAR therapies. We will trace how flow cytometry methods have matured alongside the CAR landscape, becoming a primary platform…

Biomarkers can move a program forward fast. Or slow it down with rework. Biomarkers shape decisions from discovery through late-stage clinical trials. But the wrong assay plan can waste time, budget and samples. In this KCAS Bio roundtable, we share practical ways to align context of use,…

The NULISA™ / Argo™ HT platform is a new, cutting-edge technology with strong potential in ultra-sensitive biomarker detection and targeted proteomics. In this webinar, KCAS Bio shares how we leverage this technology for the analysis of low-abundance biomarkers. Abstract In drug development, ultrasensitive bioanalytical…

This webinar is a collaboration between Sciex and KCAS Bio. Exploring cutting-edge methods for analyzing oligonucleotides in biological matrices. Oligonucleotide therapeutics have gained recent popularity given their vast applications in genetic disorders, cancers and infectious diseases. There are many challenges when developing bioanalytical methods for the quantitation…

In the evolving landscape of drug development, biomarkers are increasingly vital in driving decisions across preclinical and clinical studies. From patient stratification and efficacy monitoring to safety assessments and pharmacodynamic evaluations, biomarkers are critical tools for reducing development timelines and increasing the likelihood of regulatory success. But with so…

As the field of biotherapeutics rapidly evolves, the development of advanced conjugated therapies such as Antibody-Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), siRNA/oligos, and antibody-peptide conjugates has gained significant momentum. These next-generation therapeutics offer promising efficacy and safety profiles for treating various conditions, including cancer, rare diseases, and in vaccine…

In this discussion, our panelists examine oligonucleotide bioanalysis assessment strategies, including quantification via LBA, LC–MS/MS and hybrid assays, as well as the emerging technologies and the future direction of this rapidly evolving field. In 1998, the first oligonucleotide therapy was approved for commercial use and since then many…

Webinar Description: Acquire a deeper understanding of Receptor Occupancy (RO) assays as measured by flow cytometry.  We will discuss the fundamental considerations for RO method design, development, and validation.  Within each of these areas, Dr. Evans highlights critical areas of consideration which can impact your ability to robustly quantify Receptor Occupancy…

Webinar Description: KCAS Bio will present results from a recent validation of two IP panels on the Cytek Aurora in PBMCs. We have analyzed the impact of different fixation buffers on the efficacy of reference controls over time, and we will explore how to help improve workflow standards and…

Webinar Description: Biomarkers are a critical aspect of bioanalytical testing, as they provide a vast amount of information, from the effects of a drug on the subject to determining the drug’s mechanism of action and the correct dose for a patient. When developing a biomarker, it is important to…